The failure of Cel-Sci’s immunotherapy treatment called Multikine to prolong the survival of patients with head and neck cancer has pushed the tiny biotech to the precipice of insolvency. The only remaining uncertainty is how long Cel-Sci’s management team can delay the inevitable shutdown.
That might be years if biotech history — and the company’s penchant for misleading investors about Multikine — is any guide. The company’s already-plunging share price, however, isn’t likely to prove so durable.
Create a display name to comment
This name will appear with your comment